171 related articles for article (PubMed ID: 31622673)
21. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
23. The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1).
Smith J; Allman D; Badri H; Miller R; Morris J; Satia I; Wood A; K Trower M
Chest; 2020 Jan; 157(1):111-118. PubMed ID: 31421110
[TBL] [Abstract][Full Text] [Related]
24. Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting.
Jin Z; Daksla N; Gan TJ
Drugs; 2021 Jul; 81(10):1171-1179. PubMed ID: 34106456
[TBL] [Abstract][Full Text] [Related]
25. NK1 receptor antagonists for depression: Why a validated concept was abandoned.
Rupniak NMJ; Kramer MS
J Affect Disord; 2017 Dec; 223():121-125. PubMed ID: 28753469
[TBL] [Abstract][Full Text] [Related]
26. TRPV1 antagonists as potential antitussive agents.
McLeod RL; Correll CC; Jia Y; Anthes JC
Lung; 2008; 186 Suppl 1():S59-65. PubMed ID: 17926096
[TBL] [Abstract][Full Text] [Related]
27. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.
Hay DW; Giardina GA; Griswold DE; Underwood DC; Kotzer CJ; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Martin LD; Kilian D; Legos JJ; Barone FC; Luttmann MA; Grugni M; Raveglia LF; Sarau HM
J Pharmacol Exp Ther; 2002 Jan; 300(1):314-23. PubMed ID: 11752131
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin-1 Receptor Inhibition and Cough.
Turner RD; Birring SS
Am J Respir Crit Care Med; 2021 Mar; 203(6):672-674. PubMed ID: 33108214
[No Abstract] [Full Text] [Related]
29. Regulating cough through modulation of sensory nerve function in the airways.
Spina D; Page CP
Pulm Pharmacol Ther; 2013 Oct; 26(5):486-90. PubMed ID: 23524012
[TBL] [Abstract][Full Text] [Related]
30. Central regulation of the cough reflex: therapeutic implications.
Canning BJ
Pulm Pharmacol Ther; 2009 Apr; 22(2):75-81. PubMed ID: 19284972
[TBL] [Abstract][Full Text] [Related]
31. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
Garceau D; Chauret N
Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
[TBL] [Abstract][Full Text] [Related]
32. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
33. The current and emerging treatment landscape for chronic cough.
Dicpinigaitis P
Am J Manag Care; 2022 Sep; 28(9 Suppl):S159-S165. PubMed ID: 36198074
[TBL] [Abstract][Full Text] [Related]
34. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
[TBL] [Abstract][Full Text] [Related]
35. Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.
Jones JD; Speer T; Comer SD; Ross S; Rotrosen J; Reid MS
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):86-91. PubMed ID: 23421568
[TBL] [Abstract][Full Text] [Related]
36. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
37. Increased blocking activity of combined tachykinin NK1- and NK2-receptor antagonists on tachykinergic bronchomotor responses in the guinea-pig.
Corboz MR; Fernandez X; Rizzo CA; Tozzi S; Monahan ME; Hey JA
Auton Autacoid Pharmacol; 2003 Feb; 23(1):79-93. PubMed ID: 14565542
[TBL] [Abstract][Full Text] [Related]
38. Tachykinin receptor antagonists and cough.
Advenier C; Emonds-Alt X
Pulm Pharmacol; 1996; 9(5-6):329-33. PubMed ID: 9232671
[TBL] [Abstract][Full Text] [Related]
39. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
[TBL] [Abstract][Full Text] [Related]
40. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
Chasen MR; Rapoport BL
Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
